Inspirata Announces New Software Release and Partnership with Hamamatsu at Digital Pathology & AI Congress in London, December 6-7
Visit stand 30 at the 5th Digital Pathology and AI Congress, London to learn how Inspirata is igniting digital pathology with new software features and functions in release v2.0.8.
London, United Kingdom, Dec. 05, 2018 (GLOBE NEWSWIRE) -- London, United Kingdom, December 5, 2018/Globe Newswire – Cancer informatics and digital pathology workflow solution provider Inspirata® Europe, Ltd. today revealed it has entered into a partnership agreement with Hamamatsu Photonics affording shared customers with the ability to view native Hamamatsu .ndpi images within Inspirata’s Dynamyx™ digital pathology software. Inspirata and Hamamatsu will also be showcasing the many benefits this technical partnership will bring to clinical laboratories as part of both providers’ scheduled participation in Digital Pathology & AI Congress, London.
“By bringing on new leading scanner partners and enhancing the viewer capabilities, Dynamyx™ is positioning itself as the nucleus of a digital pathology ecosystem,” says Inspirata Founder Dr. Mark Lloyd. “We are thrilled to be seamlessly integrated with the high quality Whole Slide Images produced by the diverse line of Hamamatsu scanners, as it gives our joint clients an exemplary user experience while protecting any previous investment in scanners and allowing for the growth of new instruments.”
The Hamamatsu integration is included as part of release v2.0.8, comes just three months after Inspirata’s last major update and further exemplifies the partnership philosophy which underpins their mission and vision. “We are bringing scanners, image analysis algorithms and AP-LIS/ LIMS vendors together to create a comprehensive digital workflow which empowers pathologists to work more efficiently and effectively,” says General Manager of Inspirata Europe, Ltd. Tim Wing. “With the Royal College of Pathologists’ 2018 Histopathology Workforce Surveyi surfacing just three percent of histopathology departments in the UK possess sufficient staff to meet demand, equipping those covering the shortfall to work smarter is imperative. The pathology and laboratory community are desperately appealing for providers to work closer together for the betterment of patients and this partnership speaks to what can be achieved when they do.”
“Hamamatsu Photonics is delighted to collaborate with Inspirata and is excited that our renowned range of WSI scanners will form a key part of such an integrated digital pathology workflow solution,” explains Hamamatsu Photonics Europe Nanozoomer Product Manager Emmanuel Pirson. “We expect this partnership to contribute to an accelerated uptake of integrated digital pathology solutions within the European clinical market. Likewise, this collaboration represents just one of a number of steps our Company is taking to increase awareness and acceptance of digital pathology.”
With orders placed for a single Nanozoomer S60 and two Nanozoomer S360, one of the early beneficiaries of the Inspirata and Hamamatsu partnership will be Path Links in Lincoln. Representing one of the largest clinical pathology networks in the UK, Path Links serves a population of approximately one million and processes four and a half million specimens each year. “When undertaking a transformation as significant as migrating from analogue to digital pathology, it is essential to have the freedom as an institution to select the blend of providers which most appropriately match your requirements,” says Mick Chomyn, Path Links General Manager. “Having spent the last few months really putting them through their paces, we are confident that the Hamamatsu scanners represent an excellent fit and will serve to complement our existing scanner investments.”
Located at stand 30 at Digital Pathology & AI Congress, event attendees will be able to participate in interactive demonstrations of the Dynamyx digital pathology workflow software and explore for themselves how real-time collaboration, case-sharing, workflow algorithms and AI-based image analysis APIs functionality could be utilized to assist their laboratory reduce turnaround times. In addition, Inspirata and Hamamatsu will be participating in a joint Congress workshop in which they will spotlight their new integration on December 7th 1.45-2.30. Registration for this workshopii is now open and can be accessed via the link here.
The pressures on pathology departments are increasing. Inspirata’s advanced workflow-centric tools and ‘open’ architecture are critical enablers of digital adoption as a way to alleviate these challenges.
About Hamamatsu Photonics
Hamamatsu has a decade of real world experience in delivering sophisticated whole slide imaging (WSI) solutions across the globe. Hamamatsu’s NanoZoomer whole slide scanner series quickly transform entire histology and cytology glass slides into diagnostic-quality digital images for duplication, annotation, storage, retrieval, and image sharing. Our intuitive viewer software and patented navigation map technique enable users to scan slides in a variety of modes and share images across networks. Applications include routine and computer-aided diagnosis in laboratories, research, education, and telepathology.
About Inspirata Europe Ltd.
Inspirata® Europe Ltd. provides oncology diagnostics workflow solutions that span digital pathology; diagnostic and predictive assays; and precision medicine. It also offers cancer informatics workflows that, in combination with its Natural Language Processing (NLP) and Artificial Intelligence (AI) algorithms structures unstructured case files and clinician notes to provide key insights for oncology-specific clinical and operational activities as well as cancer reporting. Inspirata’s flagship solution is its Cancer Information Data Trust (CIDT) that generates a longitudinal view of oncology patients—from diagnosis, through treatments and therapies, to outcomes. The CIDT has extensive applications in clinical decision support, research, education, drug discovery and clinical trials enrollment. Its use will extend to physicians, patients, researchers, pharma and others. For more information, please visit www.inspirata.com or contact firstname.lastname@example.org.
i Royal College of Pathologists Histopathology Workforce Survey – link here
ii The workshop is only open to those registered to attend Digital Pathology & AI Congress.
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
WillScot Announces Closing of Warrant Exchange Offer11.12.2018 22:05 | Pressemelding
BALTIMORE, Dec. 11, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”) (NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced the closing of its previously announced exchange offer (the “Exchange Offer”) relating to certain outstanding warrants issued in 2015 (the “Warrants”). Under the terms of the Exchange Offer, each Warrant holder had the opportunity to receive 0.18182 shares of WillScot Class A Common Stock, par value $0.0001 per share (“Common Stock”), for each Warrant tendered by the holder and exchanged pursuant to the Exchange Offer. As of the closing of the Exchange Offer on December 11, 2018, 45,131,827 outstanding Warrants were properly tendered and not withdrawn in the Exchange Offer. 45,031,827 of the Warrants tendered were public warrants, representing approximately 89% of the public warrants, and approximately 100,000 Warrants tendered were private warrant
DoubleVerify and InMobi Unite to Combat Mobile App Fraud11.12.2018 18:02 | Pressemelding
Partnership brings mobile app fraud prevention to advertisers globally NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- DoubleVerify ("DV"), the leading independent provider of marketing measurement software and analytics, today announced a partnership with InMobi, a global provider of enterprise platforms for marketers. As part of the partnership, DoubleVerify will provide always-on fraud filtering and measurement for mobile in-app advertising campaigns across the InMobi Exchange globally. The integration with InMobi covers pre-bid targeting for all InMobi Exchange impressions within the leading mobile in-app platform, as well as monitoring of post-bid fraud activity, such as spoofing – enabling InMobi to continuously refine the quality of its mobile ad inventory. “DV’s partnership with InMobi demonstrates our commitment to provide consistent, comprehensive quality coverage for global brand advertisers,” said Matt McLaughlin, COO at DoubleVerify. “With ad spend increasingly concentrated in
Claroty Announces Major Enhancements to Market-Leading Industrial Cybersecurity Platform11.12.2018 15:00 | Pressemelding
Groundbreaking multispectral data acquisition and network segmentation capabilities provide deeper OT network visibility and reduce risk for industrial enterprises and critical infrastructure providers NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Claroty, the leader in operational technology (OT) network protection, today announced several significant enhancements to its award-winning Continuous Threat Detection product and technology integrations with several leading industrial automation, network infrastructure and cybersecurity providers. Already the industry’s most complete industrial control systems (ICS) cybersecurity platform, this release incorporates new functionality to provide even more “extreme” visibility into ICS networks and help industrial enterprises decrease the risk of a cyberattack. The latest release of Claroty Continuous Threat Detection provides a large number of significant enhancements including: Virtual Zones and OT Network Segmentation – an innovative approach
INN Launches Battery Metals Channel11.12.2018 15:00 | Pressemelding
The new battery metals channel is designed to educate investors with original content and expert insight on the growing battery metals industry. VANCOUVER, British Columbia, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Investing News Network (INN) announces the launch of its battery metals channel. Responding to the growth and evolution of the battery metals market, this channel will host news, educational content and expert opinions on the lithium, cobalt, graphite, vanadium and manganese market segments. “INN has been a trusted source of information on the lithium, cobalt, graphite, vanadium and manganese markets for nearly a decade, and is excited to bring these sectors together under the battery metals umbrella,” said Nick Smith, CEO and publisher at INN. “Through connections with experts, our leading team of experienced writers creates original, insightful content on battery metals. INN educates investors in the industry by providing information they may never have access to on their own,” S
Galimedix Therapeutics Appoints Industry Veteran, Hermann Russ, M.D., Ph.D., Chief Scientific Officer11.12.2018 14:30 | Pressemelding
KENSINGTON, Md. and SHORASHIM, Israel, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Galimedix Therapeutics, which is developing new solutions for ophthalmic and neurodegenerative diseases, announced the appointment of Hermann Russ, M.D., Ph.D., as its chief scientific officer, effective December 1, 2018. Dr. Russ invented the use of the company’s lead molecule GAL-101/MRZ-99030 for the treatment of degenerative diseases of the retina, including glaucoma and dry macular degeneration. He is also co-inventor of the so-called “trigger effect” of GAL-101/MRZ-99030 and GAL-102/MRZ 14042, which is a unique reverse prion-like self-propagation mechanism of action important for the company’s eye drop and oral treatment regimens. “We are gratified that Dr. Russ is joining the Galimedix management team, as his knowledge in the field, as well as intimate experience with the compound, have already proven instrumental in the development of our company to date,” commented Andrew Pearlman, Ph.D., CEO of Galimedix
Farmako: Cannabis distributor to become gateway to Europe11.12.2018 10:00 | Pressemelding
Company is first to apply for a licence in the United Kingdom AAA-Team pushes to become gateway to Europe Company first to apply for distribution licences in UK Support of Canadian LP to obtain EU-GMP Focus on research and development FRANKFURT, Germany, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The Frankfurt-based pharmaceutical company Farmako is a research-based pharmaceutical company that distributes medical cannabis. The company is active in all European markets that have created a legal basis for cannabinoid therapies. It is the first company for medical Cannabis pursue distribution licences in multiple European countries. Fort hat, it will rely on EU-GMP certified suppliers. The German market for medical cannabis is estimated at 19.1 million euros in 2018 and at 200 million Euros by 2019. For 2028, experts expect a market volume for medical cannabis of 7.8 billion euros in Germany, an increase by a factor of 400. The number of patients for cannabinoid therapies in Germany has grown from
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom